Studying Why Some Migraine Patients Respond Poorly to Triptans
Compares tryptophan levels in migraine patients who respond to triptans and those who do not.
Key facts
- Who runs it
- University Hospital, Clermont-Ferrand
- Where
- Clermont-Ferrand, FranceSee the site
- Trial code
- Registry title
- Tryptophan as a Modulating Factor in the Antimigraine Efficacy of Triptans
- Status
- Recruiting
- People taking part
- 144 people, planned
- Started
- 5 Mar 2026
- Expected to end
- Mar 2028
- Type of study
- Observational, 2 groups
- Treatments tested
- Blood collection
- Record updated
- 9 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 50 with migraine who have been found to respond, or not respond, to triptan medicines.
- Age
- 18 to 50 years.
- Sex
- Women (before menopause) and men can join.
- Disease stage
- Migraine diagnosed by ICHD-3 criteria. Must be classed as a responder or non-responder to triptans (criteria of Sacco et al., 2022).
- Earlier treatment
- Triptans used alone or with other migraine treatments such as NSAIDs, acetaminophen, ergotamine, opioids or antiemetics. All routes and all doses are allowed.
Main reasons for not taking part
- Patients under guardianship, curatorship, deprivation of liberty or legal protection
- Pregnant women
- Breastfeeding women
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Cisgender women, premenopausal, aged 18 to 50 years
- Cisgender men, aged 18 to 50 years
- Diagnosed with migraine (according to ICHD-3 criteria)
- Diagnosed as responders or non-responders to triptans (according to the criteria of Sacco et al., 2022)
- Permitted comparison groups include: triptans used alone or in combination with other migraine treatments (e.g., NSAIDs, acetaminophen, ergotamine, opioids, antiemetics)
- All routes of administration and all dosages
- Affiliation with a social security system
Who cannot take part
- Patients under guardianship, curatorship, deprivation of liberty, or legal protection
- Pregnant and breastfeeding women
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Where in France
- CHU de Clermont-FerrandClermont-Ferrand, FranceContact: Lise LaclautreTaking people
About the trial
What the trial wants to find out
Migraine is a leading cause of disability, and while triptans are commonly used to treat migraine attacks, over 20% of patients don't respond well to them. This study aims to understand why some people don't benefit from triptans. One key focus is tryptophan, an amino acid that plays a role in migraine and is involved in producing serotonin, which affects pain and inflammation. The study will compare levels of tryptophan and its by-products in patients who respond well to triptans versus those who don't. It will also look at how conditions like inflammatory bowel disease may affect tryptophan absorption. The goal is to improve migraine treatments tailored to different patient needs, though participants may not experience immediate personal benefits.
The 2 groups in the trial
- Migraineurs responding to triptans
Blood collection
Treatment: Blood collection
- Migraine sufferers resistant to triptans
Blood collection
Treatment: Blood collection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Tryptophan as a Modulating Factor in the Antimigraine Efficacy of Triptans
- Plain-language title
- Studying Why Some Migraine Patients Respond Poorly to TriptansGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07177885, who can take part
- Record updated
- 9 March 2026